OLAPARIB-IDH-SARC
Regimen
- Experimental
- Olaparib 300 mg PO BID continuous (PARP inhibitor)
- Control
- none (single-arm)
Population
Advanced IDH1- or IDH2-mutant mesenchymal sarcomas (chondrosarcoma dominant, plus cholangiocarcinoma excluded per design), refractory to standard therapy
Key finding
PARP inhibition in IDH-mutant chondrosarcoma produced durable disease stabilization in the majority of patients, establishing a second biomarker-driven strategy after IDH1 inhibition. Small N but mechanistically coherent.
Source: PMID 34994649